Dr Egeland is senior director of business development and licensing in the Early Technologies business unit of the Minimally Invasive Therapies Group at Medtronic. Mr Rapp is an associate consultant at Pharmagellan, a biotech consultancy. Dr David is the founder and managing director of Pharmagellan.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.surg.2017.04.007 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Energy-poverty-inequality SDGs: A large-scale household analysis and forecasting in China.
Proc Natl Acad Sci U S A
January 2025
Department of Biology, Stanford University, Stanford, CA 94305.
Affordable and clean energy, eliminating poverty, and reducing inequality are important goals of the United Nations Sustainable Development Goals (SDGs). This paper examines the role of access to clean cooking fuels in promoting income growth and reducing income inequality. Using data from Chinese households, we show that a 10% increase in the adoption of clean cooking fuels would result in an increase in total annual household income of US$37 billion nationwide.
View Article and Find Full Text PDFThe impact of de-familization on green innovation: Evidence from SRDI family firms in China.
PLoS One
January 2025
Institute for Chengdu-Chongqing Economic Zone Development, Chongqing Technology and Business University, Chongqing, China.
Green innovation is essential for sustainable development, especially in China's Specialized-Refined-Differentiated-Innovative (SRDI) enterprises. Family-owned SRDI firms, in particular, have attracted attention due to their de-familization strategies and their influence on green innovation. Our study analyzes panel data from 2016 to 2021 for listed SRDI family firms to investigate how de-familization in management rights and ownership impacts green innovation.
View Article and Find Full Text PDFA hybrid dual-branch model with recurrence plots and transposed transformer for stock trend prediction.
Chaos
January 2025
School of Electrical Engineering and Automation, Tianjin University, Tianjin 300072, China.
Stock trend prediction is a significant challenge due to the inherent uncertainty and complexity of stock market time series. In this study, we introduce an innovative dual-branch network model designed to effectively address this challenge. The first branch constructs recurrence plots (RPs) to capture the nonlinear relationships between time points from historical closing price sequences and computes the corresponding recurrence quantifification analysis measures.
View Article and Find Full Text PDFImpact of the Cooperative Health Insurance System in Saudi Arabia on Universal Health Coverage-A Systematic Literature Review.
Healthcare (Basel)
January 2025
Department of Health Services Research, Care and Public Health Research Institute-CAPHRI, Maastricht University Medical Center, Faculty of Health, Medicine and Life Sciences, Maastricht University, P.O. Box 616, 6200 MD Maastricht, The Netherlands.
Background: This systematic review assesses the role of the Cooperative Health Insurance System (CHIS) in achieving Universal Health Coverage (UHC) in Saudi Arabia's evolving healthcare system by consolidating and analyzing findings from diverse studies to provide a comprehensive overview of CHIS's impact and also identifies contextual challenges and practical insights that can inform similar reforms globally.
Methods: We report results following the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines. The following six databases were searched for relevant studies: PubMed, Scopus, CINAHL, Business Source Complete, APA PsycINFO, and SocIndex.
Common pitfalls in oncology drug applications aiming for conditional marketing authorization.
Br J Clin Pharmacol
January 2025
Parexel International, Durham, North Carolina, USA.
Early approval mechanisms, such as conditional approval in the EU, have been used extensively to provide timely access to therapeutic innovations to cancer patients with unmet medical needs. While based on promising early evidence, such approvals are challenging from many perspectives due to the lack of comprehensive data. The limitation typically relates to data that demonstrates clinical benefit via early endpoints and is only acceptable when the early evidence is particularly convincing to assume that the benefits of early access are greater than the potential harms.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!